Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Trial of Checkpoint Blockade in Lung CancEr Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)

NCT06732401 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT06732401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06732401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Trial of Checkpoint Blockade in Lung CancEr Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 7, 2025
Completion date
June 30, 2028
Enrollment
630 (estimated)
Sites
192

Conditions

As the registry lists them; a condition with its own page is linked.

lung non-small cell carcinoma, stage ii lung cancer ajcc v8, stage iiia lung cancer ajcc v8, stage iiib lung cancer ajcc v8